health
HER2-targeted four-drug therapy shows activity in advanced biliary cancer
A South Korean phase 1b/2 trial found a 55% objective response rate when trastuzumab and nivolumab were added to gemcitabine and cisplatin for previously untreated HER2-positive advanced biliary tract cancer. The single-arm results provide early evidence for first-line HER2-targeted chemoimmunotherapy, while randomized confirmation is still needed.